Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Uni-Bio Science GroupUNBSF 58 EBITDA Margin % is 8.56% as of Dec. 2025, which is 27% above its 10-year median of 6.72. GuruFocus rates UNBSF with a GF Score™ of 58/100 and a GF Value™ of $0.01. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Uni-Bio Science Group ranks better than 79.56% on this metric.
Uni-Bio Science Group (OTCPK:UNBSF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Uni-Bio Science Group EBITDA Margin % Related Terms
Uni-Bio Science Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Uni-Bio Science Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UNBSF vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Uni-Bio Science Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uni-Bio Science Group EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Uni-Bio Science Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Uni-Bio Science Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Uni-Bio Science Group (UNBSF) has a EBITDA Margin % of 8.56% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Uni-Bio Science Group and its competitors. This is 27% above median its historical median of 6.72. According to the industry distribution chart, Uni-Bio Science Group ranks #193 out of 944 companies in the Biotechnology industry, placing it in the top 20.4%.
Is Uni-Bio Science Group's EBITDA Margin % too high?
Uni-Bio Science Group's current EBITDA Margin % of 8.56% is 27% above median its 10-year median of 6.72. Based on the distribution chart, Uni-Bio Science Group ranks #193 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Uni-Bio Science Group has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Uni-Bio Science Group's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Uni-Bio Science Group ranks #193 out of 944 companies for EBITDA Margin %. This places Uni-Bio Science Group in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Uni-Bio Science Group and its competitors. Uni-Bio Science Group's current EBITDA Margin % is 8.56%, which is 27% above median its own 10-year median of 6.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uni-Bio Science Group stock overvalued right now?
Uni-Bio Science Group (UNBSF) has a current EBITDA Margin % of 8.56%. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 60% below its estimated fair value. The current EBITDA Margin % is 8.56%, which is 27% above median its 10-year median of 6.72. Uni-Bio Science Group's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Uni-Bio Science Group (UNBSF), the current EBITDA Margin % is 8.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uni-Bio Science Group (UNBSF) Overvalued in 2026?
Based on GuruFocus' analysis, Uni-Bio Science Group stock appears to be undervalued.
The current stock price of $0.00 is trading 60% below its estimated GF Value™ of $0.01.
Key valuation signals for UNBSF:
EBITDA Margin %: 8.56% (27% above median its 10-year median of 6.72)
GF Value™: $0.01 vs. price of $0.00 (60% below fair value)
No single metric tells the full story. See the UNBSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uni-Bio Science Group Ltd is an investment holding company. It operates in three segments: Chemical pharmaceutical products, Biological pharmaceutical products, and Pipeline products. Its geographical segments are Hong Kong and China, of which all of its revenue comes from China. The company products include GeneSoft, GeneTime, Pinup, Boshutai, Bokangtai, and others. All of the company revenue is generated from PRC.
58GF Score
Get the complete analysis for UNBSF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UNBSF has been successfully added to your 
